Skip to main content

Table 1 Baseline demographic and clinical characteristics of historical control and intervention groups

From: Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study

Variable

Historical control group

Intervention group

p-value

N

90

113

 

Demographics

 Age (years), Median (Q1, Q3)

41.0 (33.0, 50.0)

38.0 (30.0, 47.0)

0.15

 Gender, Male

66 (73.3%)

76 (67.3%)

0.35

Race

  

0.64

 White

41 (45.6%)

56 (49.6%)

 

 Black/other

49 (54.4%)

57 (50.4%)

 

 Ethnicity, Hispanic

a(1.1%–11.1%)

a(0.9%–8.8%)

0.43

Insurance

  

0.01

 Uninsured

32 (35.6%)

47 (41.6%)

 

 Medicare/Medicaid

28 (31.1%)

48 (42.5%)

 

 Private

30 (33.3%)

18 (15.9%)

 

Medical history

 Current smoker

64 (75.3%)

79 (71.2%)

0.52

 Prior smoker

a(1.1%–11.1%)

a(0.9%–8.8%)

0.90

Clinical characteristics

 Diabetes

a(1.1%–11.1%)

14 (12.4%)

0.048

 HCV infection [Sample et al.]

11 (12.2%)

17 (15.0%)

0.56

 HIV infection[Cochran]

0 (0.0%)

a(0.9%–8.8%)

0.37

 Staphylococcus aureus infection [MRSA or MSSA]

0 (0.0%)

a(0.9%–8.8%)

0.20

 Chronic Pain

a(1.1%–11.1%)

a(0.9%–8.8%)

0.58

 Depression

16 (17.8%)

18 (15.9%)

0.73

 Schizophrenia spectrum and other psychotic disorders

a(1.1%–11.1%)

a(0.9%–8.8%)

0.49

 Bipolar disorder

a(1.1%–11.1%)

a(0.9%–8.8%)

0.58

Inpatient visits and ED visits

 Number of all-cause hospitalizations in prior 12 months, Mean (SD), Median (Q1, Q3)

0.3 (0.7), 0.0 (0.0, 0.0)

0.4 (0.8), 0.0 (0.0, 0.0)

0.30

 Number of ED visits in prior 12 months, Mean (SD), Median (Q1, Q3)

2.8 (4.2), 2.0 (0.0, 3.0)

3.2 (6.5), 1.0 (0.0, 3.0)

0.14

  1. *Cells containing a value of 1 to 10 or additional cells that allow the back calculation of those small cells were suppressed in accordance with Duke EHR cell suppression policy. The range of percentages shown in parentheses indicate the possible range of values based on the suppressed cells